Home > Oncology > ASCO 2019 > Multiple Myeloma > Anti-CD38 antibody isatuximab improves treatment response, PFS in R/R multiple myeloma

Anti-CD38 antibody isatuximab improves treatment response, PFS in R/R multiple myeloma

Presented By
Dr Paul G. Richardson, Dana-Farber Cancer Institute/Harvard Medical School, USA
Conference
ASCO 2019
Trial
Phase 2, ICARIA-MM
Medical writer: Emily Kuhl, PhD A novel anti-CD38 monoclonal antibody, isatuximab, may be a key player in improving progression-free survival (PFS) and treatment response among patients with relapsed/refractory multiple myeloma (RRMM). “Isatuximab has become a breakthrough target in multiple myeloma therapy and is an important new treatment option for patients with RRMM,” co-investigator Paul G. Richardson, MD, of the Dana-Farber Cancer Institute and Harvard Medical School, said during his presentation on June 2 (Abstract 8004). A previous phase Ib study showed that isatuximab combined with pomalidomide and dexamethasone was safe and effective for RRMM. Based on this, ICARIA-MM, a phase III, randomized, open-label, multicentre trial (NCT02990338), was initiated to examine the combination of isatuximab plus pomalidomide vs. pomalidomide alone. This was the first randomized phase III study to investigate the addition of an anti-CD38 antibody to pomalid...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on